Advertisement
Stephen Jones, M.D., medical director for US Oncology Research, co-chair of the US Oncology Breast Cancer Research Committee, and physician at Texas Oncology-Dallas, and Lina Asmar, Ph.D., director of Biostatistics and Medical Writing at US Oncology, were co-authors on a team that presented results at 9:15 a.m. on Thursday, Dec. 10, regarding the five-year analysis of the TEAM (Tamoxifen Exemestane Adjuvant Multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer. The study was titled "Five years of exemestane as initial therapy compared to 5 years of tamoxifen followed by exemestane: the TEAM trial, a prospective, randomized, phase III trial in postmenopausal women with hormone-sensitive early breast cancer."
Advertisement
"The TEAM trial is the largest aromatase inhibitor study ever to be conducted. The overall results are positive with an improvement in outcome measured by several parameters and a favorable safety profile for exemestane relative to a worldwide standard, tamoxifen," said Dr. Jones. "This very large study is a treasure trove of substudies, providing valuable scientific information for women with breast cancer."
Dr. Jones was also an investigator in Thursday's 9:30 a.m. oral presentation, titled, "Disease related outcome with long term follow-up: an updated analysis of the Intergroup Exemestane Study (IES)" and several poster sessions listed below. Dr. Asmar also co-authored many of the poster presentations listed below.
Nicholas Robert, M.D., investigator at Fairfax-Northern Virginia Hematology-Oncology, an affiliate of US Oncology, participated in three oral presentations at the symposium:
Dr. Robert also co-authored many poster sessions listed below.
Ragene Rivera, M.D., investigator at Texas Oncology-El Paso West, an affiliate of US Oncology, participated in the RIBBON-2 study: "A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of Bevacizumab in combination with chemotherapy for second-line treatment of HER@-negative metastatic breast cancer" presented orally at 3 p.m. Friday, Dec. 11.
Joyce O'Shaughnessy, M.D., investigator with Texas Oncology-Baylor at Sammons Cancer Center, an affiliate of US Oncology, was an investigator on the team that presented the 9:30 a.m. general session on Saturday, Dec. 12 titled, "Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy." Dr. O'Shaughnessy also co-authored several poster sessions listed below.
In addition to the above oral presentations, US Oncology affiliated physicians presented the following poster sessions:
Poster session 1, Thursday, Dec. 10:
Poster session 2, Friday, Dec. 11:
Poster session 3
Poster session 5
Poster session 6
About US Oncology Research
With experienced investigators and dedicated research nurses, US Oncology Research represents the largest research network specializing in Phase I-IV oncology clinical trials in the United States. US Oncology Research serves more than 80 sites in 200 locations with over 70 open trials being managed at any given time.
Supported by US Oncology, Inc., the network has played a role in the development of 39 cancer therapies approved by the Food and Drug Administration; more than 38,500 patients have participated in clinical trials. For more information, visit the company's Web site, www.usoncology.com.
About US Oncology
US Oncology, Inc., headquartered in The Woodlands, Texas, works closely with physicians, payers, biotechnology, pharmaceutical and medical equipment manufacturers, to identify and deliver innovative services that enhance patient access to advanced cancer care. US Oncology supports one of the nation's foremost cancer treatment and research networks, accelerating the availability and use of evidence-based medicine and shared best practices.
US Oncology uses its expertise to support every aspect of the cancer care delivery system--from drug development to distribution and outcomes measurement--enabling the company to help increase the efficiency and safety of cancer care. According to the company's last quarterly earnings report, US Oncology is affiliated with 1,310 physicians operating in 493 locations, including 98 radiation oncology facilities in 39 states. For more information, visit the company's Web site, www.usoncology.com.
-- The 9:45 a.m. oral presentation on Thursday, Dec. 10, titled, "Outcomes of women who were premenopausal at diagnosis of early stage breast cancer in the NCIC CTG MA17 Trial." -- The 9:45 a.m. presentation on Saturday, Dec. 12, titled, "Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC[rarr]T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC[rarr]TH) with docetaxel, carboplatin and trastuzumab (TCH) in Her2neu positive early breast cancer patients: BCIRG 006 study." -- The 10:15 a.m. presentation on Saturday, Dec. 12, titled, "Analysis of Fcy receptor IIA & IIIA polymorphisms: correlation with outcome in trastuzumab-treated HER2/Neu amplified early and metastatic breast cancer patients."
SOURCE US Oncology
